| Security Name | Ticker | % of Net Assets |
|---|---|---|
| ABBVIE INC | ABBV | 7.62% |
| AMGEN INC. | AMGN | 5.65% |
| GILEAD SCIENCES, INC. | GILD | 4.79% |
| VERTEX PHARMACEUTICALS | VRTX | 4.16% |
| REGENERON PHARMACEUTICALS | REGN | 3.47% |
| ALNYLAM PHARMACEUTICALS | ALNY | 2.92% |
| INSMED INC | INSM | 2.84% |
| CORTEVA INC | CTVA | 2.43% |
| NATERA INC | NTRA | 2.16% |
| ASTRAZENECA PLC ADR | AZN | 2.10% |
| BIOGEN IDEC, INC. | BIIB | 1.89% |
| BEONE MEDICINES LTD-ADR | BGNE | 1.82% |
| INCYTE CORP | INCY | 1.81% |
| ILLUMINA INC | ILMN | 1.80% |
| ROYALTY PHARMA PLC- CL A | RPRX | 1.74% |
| GUARDANT HEALTH INC | GH | 1.73% |
| AVIDITY BIOSCIENCES INC | RNA | 1.58% |
| EXACT SCIENCES | EXAS | 1.48% |
| NEUROCRINE BIOSCIENCES IN | NBIX | 1.47% |
| VIATRIS INC | VTRS | 1.47% |
| BRIDGEBIO PHARMA INC | BBIO | 1.46% |
| REVOLUTION MEDICINES INC | RVMD | 1.41% |
| ARGENX SE - ADR | ARGX | 1.41% |
| IONIS PHARMACEUTICALS, IN | IONS | 1.37% |
| ROIVANT SCIENCES LTD | ROIV | 1.35% |
| UNITED THERAPEUTICS CORP | UTHR | 1.33% |
| EXELIXIS, INC. | EXEL | 1.33% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 1.29% |
| BIOMARIN PHARMACEUTICAL | BMRN | 1.22% |
| ALKERMES PLC | ALKS | 1.21% |
| CYTOKINETICS INC | CYTK | 1.20% |
| MODERNA INC | MRNA | 1.17% |
| VAXCYTE INC | PCVX | 1.08% |
| ARROWHEAD PHARMACEUTICALS | ARWR | 1.05% |
| BIONTECH SE-ADR | BNTX | 1.05% |
| PROTAGONIST THER | PTGX | 1.04% |
| HALOZYME THERAPEUTICS INC | HALO | 1.03% |
| VIKING THERAPEUTICS INC | VKTX | 1.02% |
| PTC THERAPEUTICS | PTCT | 1.00% |
| AXSOME THERAPEUT | AXSM | 0.97% |
| CRISPR THERAPEUTICS AG | CRSP | 0.97% |
| LEGEND BIOTECH CORP-ADR | LEGN | 0.90% |
| CRINETICS PHARMACEUTICALS | CRNX | 0.88% |
| NUVALENT INC-A | NUVL | 0.86% |
| AKERO THERAPEUTICS INC | AKRO | 0.85% |
| VERACYTE INC | VCYT | 0.80% |
| MEDPACE HOLDINGS | MEDP | 0.80% |
| TG THERAPEUTICS | TGTX | 0.79% |
| DYNE THERAPEUTICS INC | DYN | 0.75% |
| ADMA BIOLOGICS INC | ADMA | 0.73% |
| IDEAYA BIOSCIENCES INC | IDYA | 0.72% |
| AMICUS THERAPEUTICS INC | FOLD | 0.70% |
| ULTRAGENYX PHARM | RARE | 0.69% |
| ACADIA PHARMACEUTICALS IN | ACAD | 0.65% |
| ARCELLX INC | ACLX | 0.63% |
| MADRIGAL PHARMAC | MDGL | 0.61% |
| AGIOS PHARMACEUT | AGIO | 0.60% |
| DENALI THERAPEUT | DNLI | 0.60% |
| IMMUNOVANT INC | IMVT | 0.57% |
| SUMMIT THERAPEUTICS INC | SMMT | 0.57% |
| TWIST BIOSCIENCE CORP | TWST | 0.56% |
| BEAM THERAPEUTICS INC | BEAM | 0.54% |
| RECURSION PHARMACEUTICALS | RXRX | 0.51% |
| APELLIS PHARMACE | APLS | 0.50% |
| SAREPTA THERAPEU | SRPT | 0.49% |
| ASCENDIS PHA-ADR | ASND | 0.48% |
| CELLDEX THERAPEUTICS INC | CLDX | 0.48% |
| DYNAVAX TECHNOLOGY | DVAX | 0.47% |
| KRYSTAL BIOTECH INC | KRYS | 0.46% |
| NOVAVAX INC | NVAX | 0.39% |
| INTELLIA THERAPE | NTLA | 0.37% |
| SOLENO THERAPEUTICS INC | SLNO | 0.34% |
| IOVANCE BIOTHERAPEUTICS | IOVA | 0.22% |
| Other (Cash, derivatives and other liabilities) | 0.60% | |
| Total: | ||
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.